Alicia Ciccone, Digital Content Editor

The CaMEO study is a prospective, longitudinal web-based survey designed to characterize the impact of migraine on aspects of quality of life.

The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.

The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.

The first-in-class migraine prevention drug will be available to patients within 1 week of the approval.

Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

In patients with sciatica pain, treatment with pregabalin did not significantly reduce pain intensity compared with placebo.

The US FDA is warning physicians and patients for the second time to be aware of an experimental procedure that is being promoted as a treatment in autonomic dysfunction.

The United States Preventive Services Task Force failed to recommend routine screening for obstructive sleep apnea in asymptomatic adults.

There is a need for better assessment of autonomic symptoms in pediatric headache patients.